In a patient with infectious mononucleosis and elevated AST, ALT, alkaline phosphatase, and prolonged INR, is the hepatitis attributable to acute Epstein‑Barr virus infection?

EBV-Induced Hepatitis in Infectious Mononucleosis

Yes, elevated AST, ALT, alkaline phosphatase, and prolonged INR in a patient with infectious mononucleosis is consistent with Epstein-Barr virus-induced hepatitis, though the prolonged INR warrants careful assessment of severity and exclusion of other causes.

Pattern of Liver Involvement in EBV Infection

EBV-induced hepatitis typically presents with specific biochemical patterns that align with your patient's presentation:

• Transaminase elevation is nearly universal in infectious mononucleosis, with AST and ALT typically elevated 2-5 times the upper limit of normal, though values can occasionally exceed 10-fold elevation 1, 2.

• Alkaline phosphatase and γ-GT elevation occurs in approximately 38-59% of patients with EBV hepatitis, representing a predominantly cholestatic pattern 3, 1.

• The hepatocellular pattern (elevated transaminases) usually peaks in the first week of illness, with AST often showing two peaks—one in the first week and another in the third week 2.

• Cholestatic features (elevated ALP) tend to persist longer than transaminases, with normalization typically occurring after 20-30 days 1.

The Prolonged INR: A Critical Consideration

The presence of prolonged INR requires careful interpretation, as this is not typical of uncomplicated EBV hepatitis:

• Mild, self-limited hepatitis is the rule in EBV infection, with jaundice occurring in only 5-6% of cases and severe coagulopathy being uncommon 3, 1.

• Severe coagulopathy with marked INR elevation should prompt consideration of:

  • Acute liver failure (rare but reported in EBV) 4
  • Autoimmune hepatitis triggered by EBV infection 4
  • Drug-induced liver injury (especially if the patient received antibiotics like amoxicillin) 5
  • Wilson's disease presenting with viral trigger 6

Diagnostic Confirmation

To definitively attribute hepatitis to EBV, confirm:

• EBV VCA IgM positivity with or without EBV DNA detection in blood (≥10,000 IU/mL suggests active infection) 7, 8.

• Exclusion of other causes including hepatitis A, B, C, E, CMV, HSV, autoimmune hepatitis (ANA, ASMA, anti-LKM-1, elevated IgG), drug-induced liver injury, and Wilson's disease 6, 5.

• Autoantibody testing is particularly important because EBV can trigger autoimmune hepatitis, which would require immunosuppressive therapy rather than supportive care alone 4, 9.

Clinical Pitfalls and Management Implications

Common pitfall: Assuming all hepatitis in mononucleosis is benign. The prolonged INR in your patient suggests either:

• More severe hepatocellular injury than typical EBV hepatitis
• A second process (autoimmune hepatitis, drug injury, or underlying liver disease)

Key actions:

• Monitor synthetic function closely: Serial INR, albumin, and bilirubin 10.
• Screen for autoimmune hepatitis: The combination of EBV infection and elevated transaminases with coagulopathy can represent AIH triggered by viral infection, which requires different management 4, 9.
• Assess for acute liver failure criteria: If INR remains elevated with encephalopathy or progressive synthetic dysfunction, consider transfer to a transplant center 6.

Expected Course

In uncomplicated EBV hepatitis:

• Transaminases normalize within 20 days on average 1.
• Cholestatic markers (ALP, γ-GT) may take 20-30 days to normalize 1.
• Complete recovery is the rule in immunocompetent patients 11, 1, 2.

However, the presence of prolonged INR places your patient outside the typical benign course and mandates close monitoring and broader differential consideration 6.